https://10kdoank.wonhundred.com/products/slot-depo-10k

https://10kaja.wonhundred.com/products/slot-depo-10k

https://10kmurah.artwareeditions.com/products/slot-10k

https://nxsengine.artwareeditions.com/products/nexus-engine-slot

https://enginenxs.enamelpinfactory.com/products/nexus-slot

https://slotnxs.enamelpinfactory.com/products/nexus-slot

https://100doank.wonhundred.com/products/slot-bet-100

https://100gacor.wonhundred.com/products/slot-bet-100

https://100tong.crankbrothers.com/products/link-slot-bet-100

https://bonustong.crankbrothers.com/products/slot-bonus-100

https://bonusgacor.wonhundred.com/products/link-slot-bonus-100

https://bonusom.wonhundred.com/products/bonus-slot-100

https://rtpcakep.beziergames.com/products/rtp-slot

https://rtpgg.beziergames.com/products/rtp-slot-live

https://rtpgacor.wonhundred.com/products/rtp-slot-info

Business

Gilead is planning to send arthritis drug to the FDA this year




Gilead Sciences Inc.

GILD, + 0.40%

announced Monday afternoon that it plans to ask the food and drug administration to approve an arthritis this year. Gilead, in collaboration with Galapagos NV

GLPG, + 1.17%

has tested a substance known as filgotinib for rheumatoid arthritis, and recent study results ate investors in March. In a press release on Monday, Gilead said it met the FDA to discuss these test results recently. "As a result of this discussion, a way forward has been established to submit the NDA for filgotinib as a treatment for rheumatoid arthritis in 201[ads1]9," the release says.



Source link

Back to top button